3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and ApathyLethargy, Neurobehavioral Manifestations, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathyRecruitingPhase 1 / Phase 22026-09-03NCT07461220
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)Frontotemporal Lobar Degeneration, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, aphasia, brain disorder, central nervous system disorder, cognitive disorder, communication disorder, dementia, frontotemporal dementia, language disorder, metabolic disease, nervous system disorder, neurodegenerative disease, primary progressive aphasia, proteostasis deficiencies, psychiatric disorder, speech disorderRecruitingPhase 1 / Phase 22026-08-13NCT06064890
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32025-10-02NCT05531526